Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/25779
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BIELEN, Rob | - |
dc.contributor.author | Moreno, C. | - |
dc.contributor.author | Van Vlierberghe, H. | - |
dc.contributor.author | Bourgeois, S. | - |
dc.contributor.author | Mulkay, J. -P. | - |
dc.contributor.author | Vanwolleghem, T. | - |
dc.contributor.author | Verlinden, W. | - |
dc.contributor.author | Brixco, C. | - |
dc.contributor.author | Decaestecker, J. | - |
dc.contributor.author | de Galocsy, C. | - |
dc.contributor.author | Janssens, F. | - |
dc.contributor.author | Van Overbeke, L. | - |
dc.contributor.author | Van Steenkiste, C. | - |
dc.contributor.author | D'Heygere, F. | - |
dc.contributor.author | Cool, M. | - |
dc.contributor.author | Wuyckens, K. | - |
dc.contributor.author | Nevens, F. | - |
dc.contributor.author | ROBAEYS, Geert | - |
dc.date.accessioned | 2018-03-13T13:57:37Z | - |
dc.date.available | 2018-03-13T13:57:37Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | JOURNAL OF VIRAL HEPATITIS, 24(11), p. 976-981 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | http://hdl.handle.net/1942/25779 | - |
dc.description.abstract | Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or without pegylated interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score >= B were excluded. In total, 567 patients were included, of whom 77 were treated with PEG-IFN+DAA between 2008 and 2013 and 490 with DAA without PEG-IFN between 2013 and 2015. Patients treated with PEG-IFN+DAA (53 +/- 9y) were younger than patients treated with DAA without PEG-IFN (59 +/- 12y) (P=. 001). 47% of patients treated with PEG-IFN+DAA were in the F4 stage vs 67% of patients treated with DAA without PEG-IFN (P=. 001). Screening was inadequate in 20% of both patient groups (P=. 664). The early occurrence rate of HCC was 1.7% and 1.1% in patients treated with DAA with and without PEG-IFN, respectively (P=. 540). The early recurrence rate was 0% in patients treated with PEG-IFN+DAA and 15.0% in patients treated with DAA without PEG-IFN (P=. 857). There is no difference in early occurrence of new HCC between patients treated with DAA with and without PEG-IFN. We did observe a high early recurrence rate of HCC in patients treated with DAA without PEG-IFN. However, these patients were at baseline more at risk for HCC. Finally, in 20%, screening for HCC was inadequate. | - |
dc.description.sponsorship | This study is part of the "Limburg Clinical Research Program" (LCRP), supported by the foundation Limburg Sterk Merk, province of Limburg, Flemish government, Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital. | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.rights | © 2017 John Wiley & Sons Ltd | - |
dc.subject.other | direct-acting antiviral therapy; hepatitis C; hepatocellular carcinoma; pegylated interferon | - |
dc.subject.other | direct-acting antiviral therapy; hepatitis C; hepatocellular carcinoma; pegylated interferon | - |
dc.title | The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 981 | - |
dc.identifier.issue | 11 | - |
dc.identifier.spage | 976 | - |
dc.identifier.volume | 24 | - |
local.format.pages | 6 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Bielen, R.; Wuyckens, K.; Robaeys, G.] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. [Bielen, R.; Wuyckens, K.; Robaeys, G.] Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Genk, Belgium. [Moreno, C.] Erasme Univ Hosp, Dept Gastroenterol & Hepatopancreatol, Brussels, Belgium. [Van Vlierberghe, H.; Van Steenkiste, C.] Univ Hosp Gent, Dept Hepatol & Gastroenterol, Ghent, Belgium. [Bourgeois, S.] ZNA Stuivenberg, Dept Gastroenterol & Hepatol, Antwerp, Belgium. [Mulkay, J. -P.] Hop St Pierre & Erasme, Dept Gastroenterol & Hepatol, Brussels, Belgium. [Vanwolleghem, T.; Verlinden, W.] Antwerp Univ Hosp, Dept Gastroenterol & Hepatol, Edegem, Belgium. [Brixco, C.] CHR Citadelle, Dept Gastroenterol & Digest Oncol, Liege, Belgium. [Decaestecker, J.] AZ Delta, Dept Gastroenterol & Digest Oncol, Roeselare, Belgium. [Decaestecker, J.; Janssens, F.; D'Heygere, F.; Cool, M.; Nevens, F.; Robaeys, G.] Univ Hosp KU Leuven, Dept Gastroenterol & Digest Oncol, Leuven, Belgium. [de Galocsy, C.] Hop HIS Bracops, Dept Gastroenterol & Digest Oncol, Brussels, Belgium. [Janssens, F.] Jessa Hosp, Dept Gastroenterol & Digest Oncol, Hasselt, Belgium. [Van Overbeke, L.] AZ Sint Maarten, Dept Gastroenterol & Digest Oncol, Mechelen, Belgium. [Van Steenkiste, C.] AZ Maria Middelares, Dept Gastroenterol & Digest Oncol, Ghent, Belgium. [D'Heygere, F.] AZ Groeninge, Dept Gastroenterol & Digest Oncol, Kortrijk, Belgium. [Cool, M.] AZ Damiaan, Dept Gastroenterol & Digest Oncol, Oostende, Belgium. | - |
local.publisher.place | HOBOKEN | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1111/jvh.12726 | - |
dc.identifier.isi | 000412859300008 | - |
item.validation | ecoom 2018 | - |
item.fulltext | With Fulltext | - |
item.fullcitation | BIELEN, Rob; Moreno, C.; Van Vlierberghe, H.; Bourgeois, S.; Mulkay, J. -P.; Vanwolleghem, T.; Verlinden, W.; Brixco, C.; Decaestecker, J.; de Galocsy, C.; Janssens, F.; Van Overbeke, L.; Van Steenkiste, C.; D'Heygere, F.; Cool, M.; Wuyckens, K.; Nevens, F. & ROBAEYS, Geert (2017) The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience. In: JOURNAL OF VIRAL HEPATITIS, 24(11), p. 976-981. | - |
item.accessRights | Open Access | - |
item.contributor | BIELEN, Rob | - |
item.contributor | Moreno, C. | - |
item.contributor | Van Vlierberghe, H. | - |
item.contributor | Bourgeois, S. | - |
item.contributor | Mulkay, J. -P. | - |
item.contributor | Vanwolleghem, T. | - |
item.contributor | Verlinden, W. | - |
item.contributor | Brixco, C. | - |
item.contributor | Decaestecker, J. | - |
item.contributor | de Galocsy, C. | - |
item.contributor | Janssens, F. | - |
item.contributor | Van Overbeke, L. | - |
item.contributor | Van Steenkiste, C. | - |
item.contributor | D'Heygere, F. | - |
item.contributor | Cool, M. | - |
item.contributor | Wuyckens, K. | - |
item.contributor | Nevens, F. | - |
item.contributor | ROBAEYS, Geert | - |
crisitem.journal.issn | 1352-0504 | - |
crisitem.journal.eissn | 1365-2893 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
bielen 1.pdf Restricted Access | Published version | 341.06 kB | Adobe PDF | View/Open Request a copy |
HCC paper final version.pdf | Peer-reviewed author version | 153.91 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.